

Jill Fulcher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2571514/publications.pdf>

Version: 2024-02-01

13
papers

55
citations

1683354

5
h-index

1719596

7
g-index

15
all docs

15
docs citations

15
times ranked

124
citing authors

#	ARTICLE	IF	CITATIONS
1	Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. <i>Leukemia Research</i> , 2020, 97, 106442.	0.4	15
2	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7
3	Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. <i>Current Oncology</i> , 2021, 28, 1376-1387.	0.9	7
4	Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2295-2297.	0.6	7
5	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574.	0.5	7
6	Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia – time to reconsider current approaches?. <i>Thrombosis Research</i> , 2020, 188, 100-102.	0.8	6
7	Total body irradiation (18% Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1454-1456.	1.3	2
8	Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study. <i>Blood</i> , 2018, 132, 4850-4850.	0.6	2
9	Primary care for recipients of allogeneic hematopoietic stem cell transplantation. <i>Cmaj</i> , 2020, 192, E1538-E1538.	0.9	1
10	Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021, , 1.	0.8	1
11	Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2271-2273.	0.6	0
12	Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML. <i>Blood</i> , 2019, 134, 5156-5156.	0.6	0
13	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , 2019, 134, 3263-3263.	0.6	0